JKN23041吸入溶液治疗中、重度慢性阻塞性肺疾病(COPD)患者的安全性、有效性的随机、开放、阳性对照IIa期临床研究
[Translation] A randomized, open-label, positive-controlled phase IIa clinical study on the safety and efficacy of JKN23041 inhalation solution in the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD)
主要目的:评价不同给药频次下的JKN23041吸入溶液在COPD患者中的安全性;
次要目的:1)评价不同给药频次下的JKN23041吸入溶液在COPD患者中的有效性;2)评价JKN23041吸入溶液在COPD患者中的药代动力学特征。
[Translation] Primary Objective: To evaluate the safety of JKN23041 inhalation solution at different dosing frequencies in patients with COPD.
Secondary Objectives: 1) To evaluate the efficacy of JKN23041 inhalation solution at different dosing frequencies in patients with COPD; 2) To evaluate the pharmacokinetic characteristics of JKN23041 inhalation solution in patients with COPD.
100 Clinical Results associated with Anhui Shuobai Pharmaceutical Technology Co Ltd
0 Patents (Medical) associated with Anhui Shuobai Pharmaceutical Technology Co Ltd
100 Deals associated with Anhui Shuobai Pharmaceutical Technology Co Ltd
100 Translational Medicine associated with Anhui Shuobai Pharmaceutical Technology Co Ltd